USFDA completes inspection of Piramal Pharma with zero observation

"The company remains committed to maintain the highest standards of compliance,” Piramal Pharma said in a statement.

248
USFDA Inspection audit
USFDA Inspection

Last Updated on December 31, 2023 by The Health Master

The pharmaceutical company said that the United States Food and Drug Administration (USFDA) had conducted a good manufacturing practices (GMP) plus pre-approval inspection of Piramal Pharma’s Pithampur facility from 15 May 2023 to 19 May 2023.

The inspection was completed successfully with ‘zero’ Form – 483 observations and no action indicated (NAI) designation.

“The company remains committed to maintain the highest standards of compliance,” Piramal Pharma said in a statement.

Piramal Pharma is a pharmaceutical company that manufactures and develops a wide range of pharmaceutical solutions to reduce diseases. Piramal Pharma serves customers worldwide.

The pharmaceutical company reported a consolidated net loss of Rs 90 crore in Q3 December 2022 as against a net profit of Rs 163.37 crore in the year-ago period.

Revenue from operations rose by 11% year-on-year to Rs 1,716 crore in Q3 FY23 from Rs 1,539 crore in the year-ago period.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news